July 26, 2018
LexaGene announces that the company has begun beta development of its flagship pathogen detection system.
July 11, 2018
LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.
June 19, 2018
LexaGene announces C$5.0 Million bought deal with a syndicate of underwriters led by Canaccord Genuity Corp.
June 18, 2018
LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.
June 6, 2018
LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene's LX6 prototype.
May 29, 2018
LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product. This collaboration involves using targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with LexaGene’s microfluidic instrument.
May 15, 2018
LexaGene announces that its prototype for more effective pathogen detection is now generating data, and is capable of identifying E. coli and Staph.
April 5, 2018
LexaGene has entered into a collaboration with Ethos Veterinary Health to begin testing canine dog urine samples on LexaGene's LX6 prototype.
March 1, 2018
LexaGene appoints Jeffrey Mitchell as Chief Financial Officer of the Company. Mr. Mitchell has over two decades of financial and SEC experience
February 25, 2018
LexaGene honored as a Top 50-Ranked TSX Venture company, ranked by share price, trading volume and market capitalization.
For Marketing inquiries, please email:
info@lexagene.com
800-215-1824